Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction

Journal of Endocrinology

Volumn 229, Issue 3, 2016, Pages 245-258

  Apaijai, Nattayaporn ^a,b   Inthachai, Tharnwimol ^a   Lekawanvijit, Suree ^a   Chattipakorn, Siriporn C ^a,b   Chattipakorn, Nipon ^a,b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Metformin; Myocardial infarction; Obese insulin resistant rats; vildagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENALAPRIL; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSFORMING GROWTH FACTOR BETA; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; CARDIOTONIC AGENT; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, RAT; NITRILE; PYRROLIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIAC MUSCLE CELL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART RATE VARIABILITY; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEMODYNAMIC PARAMETERS; HISTOPATHOLOGY; INFARCTION; INSULIN RESISTANCE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LIGATION; LIPID DIET; MALE; MORTALITY RATE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; HEART RATE; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

ADAMANTANE; ANIMALS; CARDIOTONIC AGENTS; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENALAPRIL; HEART RATE; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; MYOCARDIAL INFARCTION; NITRILES; OXIDATIVE STRESS; PYRROLIDINES; RATS; RATS, WISTAR; VENTRICULAR REMODELING;

EID: 84977659591     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-16-0096     Document Type: Article

References (53)

1. Apaijai N, Pintana H, Chattipakorn SC and Chattipakorn N 2012 Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet. Endocrinology 153 3878-3885. (doi:10.1210/en.2012-1262)
2. Apaijai N, Pintana H, Chattipakorn SC and Chattipakorn N 2013 Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats. British Journal of Pharmacology 169 1048-1057. (doi:10.1111/ bph.12176)
3. Apaijai N, Chinda K, Palee S, Chattipakorn S and Chattipakorn N 2014 Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obeseinsulin resistant rats. PLoS ONE 9 e102374. (doi:10.1371/journal. pone.0102374)
4. Bailey CJ 2005 Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes, Obesity and Metabolism 7 675-691. (doi:10.1111/j.1463-1326.2005.00497.x)
5. Bui AL, Horwich TB and Fonarow GC 2011 Epidemiology and risk profile of heart failure. Nature Reviews Cardiology 8 30-41. (doi:10.1038/ nrcardio.2010.165)
6. Chattipakorn N, Incharoen T, Kanlop N and Chattipakorn S 2007 Heart rate variability in myocardial infarction and heart failure. International Journal of Cardiology 120 289-296. (doi:10.1016/j.ijcard.2006.11.221)
7. Chinda K, Palee S, Surinkaew S, Phornphutkul M, Chattipakorn S and Chattipakorn N 2013 Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. International Journal of Cardiology 167 451-457. (doi:10.1016/j.ijcard.2012.01.011)
8. Chinda K, Sanit J, Chattipakorn S and Chattipakorn N 2014 Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart. Diabetes and Vascular Disease Research 11 75-83. (doi:10.1177/1479164113516134)
9. Clerk A and Sugden PH 2006 Inflame my heart (by p38-MAPK). Circulation Research 99 455-458. (doi:10.1161/01.RES.0000241053.89089.c3)
10. Derosa G, Bonaventura A, Bianchi L, Romano D, Fogari E, D'Angelo A and Maffioli P 2014 Vildagliptin compared to glimepiride on post prandial lipemia and on insulin resistance in type 2 diabetic patients. Metabolism 63 957-967. (doi:10.1016/j.metabol.2014.04.008)
11. Fu AZ, Johnston SS, Ghannam A, Tsai K, Cappell K, Fowler R, Riehle E, Cole AL, Kalsekar I and Sheehan J 2016 Association between hospitalization for heart failure and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: an observational study. Diabetes Care [in press]. (doi:10.2337/dc15-0764)
12. Goncalves L 1995 Risk stratification after myocardial infarction. Clinical evaluation before discharge. Review Port Cardiology 14 475-482, 448.
13. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A, Anaya-Cisneros M, Tian R and Lefer DJ 2009 Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circulation Research 104 403-411. (doi:10.1161/CIRCRESAHA.108.190918)
14. Hamid T, Guo SZ, Kingery JR, Xiang X, Dawn B and Prabhu SD 2011 Cardiomyocyte NF-kappaB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovascular Research 89 129-138. (doi:10.1093/cvr/cvq274)
15. Hori M and Nishida K 2009 Oxidative stress and left ventricular remodeling after myocardial infarction. Cardiovascular Research 81 457-464. (doi:10.1093/cvr/cvn335)
16. Inthachai T, Lekawanvijit S, Kumfu S, Apaijai N, Pongkan W, Chattipakorn SC and Chattipakorn N 2015 Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction. Experimental Physiology 100 667-679. (doi:10.1113/ep085108)
17. Kiliszek M, Maczewski M, Styczynski G, Duda M, Opolski G and Beresewicz A 2007 Low-density lipoprotein reduction by simvastatin is accompanied by angiotensin II type 1 receptor downregulation, reduced oxidative stress, and improved endothelial function in patients with stable coronary artery disease. Coronary Artery Disease 18 201-209. (doi:10.1097/ MCA.0b013e32802c7cb0)
18. Kwak HB, Song W and Lawler JM 2006 Exercise training attenuates ageinduced elevation in Bax/Bcl-2 ratio, apoptosis, and remodeling in the rat heart. FASEB Journal 20 791-793.
19. Lekawanvijit S, Kompa AR, Zhang Y, Wang BH, Kelly DJ and Krum H Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardiorenal syndrome. American Journal of Physiology: Heart and Circulatory Physiology 302 H1884-H1893.
20. Lexis CP, van der Horst IC, Lipsic E, Wieringa WG, de Boer RA, van den Heuvel AF, van der Werf HW, Schurer RA, Pundziute G, Tan ES, et al. 2014a Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. JAMA 311 1526-1535.
21. Lexis CP, Wieringa WG, Hiemstra B, van Deursen VM, Lipsic E, van der Harst P, van Veldhuisen DJ and van der Horst IC 2014b Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevation myocardial infarction. Cardiovascular Drugs and Therapy 28 163-171.
22. Li J, Xu JP, Zhao XZ, Sun XJ, Xu ZW and Song SJ 2014 Protective effect of metformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention. Cardiology 127 133-139.
23. Liu J, Wang P, Zou L, Qu J, Litovsky S, Umeda P, Zhou L, Chatham J, Marsh SA, Dell'Italia LJ, et al. 2014 High-fat, low-carbohydrate diet promotes arrhythmic death and increases myocardial ischemiareperfusion injury in rats. American Journal of Physiology: Heart and Circulatory Physiology 307 H598-H608.
24. Luo G, Liu H, Luo S, Li F, Su M and Lu H 2014 Fasting hyperglycemia increases in-hospital mortality risk in nondiabetic female patients with acute myocardial infarction: a retrospective study. International Journal of Endocrinology 2014 745093.
25. Madian AG, Diaz-Maldonado N, Gao Q and Regnier FE 2011 Oxidative stress induced carbonylation in human plasma. Journal of Proteomics 2395-2416. (doi:10.1016/j.jprot.2011.07.014)
26. Manzella D, Barbieri M, Ragno E and Paolisso G 2001 Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes. American Journal of Clinical Nutrition 73 1052-1057.
27. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ and Foley JE 2005 Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 90 4888-4894.
28. McInnes G, Evans M, Del Prato S, Stumvoll M, Schweizer A, Lukashevich V, Shao Q and Kothny W 2015 Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of patients Diabetes, Obesity and Metabolism 17 1085-1092 doi (10.1111/dom.12548)
29. Miyoshi T, Nakamura K, Yoshida M, Miura D, Oe H, Akagi S, Sugiyama H, Akazawa K, Yonezawa T, Wada J, et al. 2014 Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats. Cardiovascular Diabetology 43.
30. Ocaranza MP, Godoy I, Jalil JE, Varas M, Collantes P, Pinto M, Roman M, Ramirez C, Copaja M, Diaz-Araya G, et al. 2006 Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 48 572-578. (doi:10.1161/ 01.HYP.0000237862.94083.45)
31. Oh K, Hu FB, Manson JE, Stampfer MJ and Willett WC 2005 Dietary fat intake and risk of coronary heart disease in women: 20 years of follow-up of the nurses' health study. American Journal of Epidemiology 672-679. (doi:10.1093/aje/kwi085)
32. Pavithran P, Nandeesha H, Sathiyapriya V, Bobby Z and Madanmohan T Short-term heart variability and oxidative stress in newly diagnosed essential hypertension. Clinical and Experimental Hypertension 30 486-496. (doi:10.1080/10641960802251875)
33. Pfeffer JM, Pfeffer MA, Fletcher PJ and Braunwald E 1991 Progressive ventricular remodeling in rat with myocardial infarction. American Journal of Physiology 260 H1406-H1414.
34. Pintana H, Apaijai N, Chattipakorn N and Chattipakorn SC 2013 DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. Journal of Endocrinology 218 1-11. (doi:10.1530/ JOE-12-0521)
35. Pipatpiboon N, Pintana H, Pratchayasakul W, Chattipakorn N and Chattipakorn SC 2013 DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption. European Journal of Neuroscience 37 839-849. (doi:10.1111/ejn.12088)
36. Pratchayasakul W, Kerdphoo S, Petsophonsakul P, Pongchaidecha A, Chattipakorn N and Chattipakorn SC 2011 Effects of high-fat diet on insulin receptor function in rat hippocampus and the level of neuronal corticosterone. Life Sciences 88 619-627. (doi:10.1016/ j.lfs.2011.02.003)
37. Rachmani R, Lidar M, Brosh D, Levi Z and Ravid M 2000 Oxidation of low-density lipoprotein in normotensive type 2 diabetic patients. Comparative effects of enalapril versus nifedipine: a randomized cross-over over study. Diabetes Research and Clinical Practice 48 139-145. (doi:10.1016/S0168-8227(99)00149-7)
38. Richer C, Fornes P, Cazaubon C, Domergue V, Nisato D and Giudicelli JF Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats. Cardiovascular Research 41 100-108. (doi:10.1016/ S0008-6363(98)00227-2)
39. Roell W, Lewalter T, Sasse P, Tallini YN, Choi BR, Breitbach M, Doran R, Becher UM, Hwang SM, Bostani T, et al. 2007 Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature 819-824. (doi:10.1038/nature06321)
40. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, et al. 2013 Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. New England Journal of Medicine 369 1373-1379. (doi:10.1056/NEJMcibr1308953)
41. Soraya H, Khorrami A, Garjani A, Maleki-Dizaji N and Garjani A 2012 Acute treatment with metformin improves cardiac function following isoproterenol induced myocardial infarction in rats. Pharmacological Reports 64 1476-1484. (doi:10.1016/S1734-1140(12)70945-3)
42. Soraya H, Clanachan AS, Rameshrad M, Maleki-Dizaji N, Ghazi- Khansari M and Garjani A 2014 Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction. European Journal of Pharmacology 737 77-84. (doi:10.1016/j.ejphar.2014.05.003)
43. Stambe C, Atkins RC, Tesch GH, Masaki T, Schreiner GF and Nikolic- Paterson DJ 2004 The role of p38alpha mitogen-activated protein kinase activation in renal fibrosis. Journal of the American Society of Nephrology 15 370-379. (doi:10.1097/01. ASN.0000109669.23650.56)
44. Suh S, Seo GH, Jung CH, Kim MK, Jin SM, Hwang YC, Lee BW and Kim JH Increased risk of hospitalization for heart failure with newly prescribed dipeptidyl peptidase-4 inhibitors and pioglitazone using the korean health insurance claims database. Diabetes Metabolism Journal 39 247-252. (doi:10.4093/dmj.2015.39.3.247)
45. Sutton MG and Sharpe N 2000 Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101 2981-2988. (doi:10.1161/01.CIR.101.25.2981)
46. Takahashi A, Asakura M, Ito S, Min KD, Shindo K, Yan Y, Liao Y, Yamazaki S, Sanada S, Asano Y, et al. 2013 Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice. American Journal of Physiology: Heart and Circulatory Physiology 304 H1361-H1369.
47. Wang J, Huang W, Xu R, Nie Y, Cao X, Meng J, Xu X, Hu S and Zheng Z MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. Journal of Cellular and Molecular Medicine 16 2150-2160. (doi:10.1111/j.1582-4934.2012.01523.x)
48. Wang SH, Chen DY, Lin YS, Mao CT, Tsai ML, Hsieh MJ, Chou CC, Wen MS, Wang CC, Hsieh IC, et al. 2015 Cardiovascular outcomes of sitagliptin in type 2 diabetic patients with acute myocardial infarction, a population-based cohort study in taiwan. PLoS ONE 10 e0131122.
49. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, et al. 2013 Alogliptin after acute coronary syndrome in patients with type 2 diabers. New England Journal of Medicine 369 1327-1335. (doi:10.1056/NEJMoa1305889)
50. Wong AK, Symon R, AlZadjali MA, Ang DS, Ogston S, Choy A, Petrie JR, Struthers AD and Lang CC 2012 The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. European Journal of Heart Failure 14 1303-1310. (doi:10.1093/eurjhf/ hfs106)
51. Yeh CC, Li H, Malhotra D, Turcato S, Nicholas S, Tu R, Zhu BQ, Cha J, Swigart PM, Myagmar BE, et al. 2010 Distinctive ERK and p38 signaling in remote and infarcted myocardium during post-MI remodeling in the mouse. Journal of Cellular Biochemistry 109 1185-1191.
52. Yin M, Sillje HH, Meissner M, van Gilst WH and de Boer RA 2011 Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of postmyocardial infarction heart failure. Cardiovascular Diabetology 10 85. (doi:10.1186/1475-2840-10-85)
53. Zuanetti G, Neilson JM, Latini R, Santoro E, Maggioni AP and Ewing DJ Prognostic significance of heart rate variability in postmyocardial infarction patients in the fibrinolytic era. The GISSI-2 results. Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico. Circulation 94 432-436. (doi:10.1161/01.CIR.94.3.432)